Simcere Pharmaceutical Group Limited (S2P.F)

0,6800 +0,0100 (+1,49%) Börsenschluss: 08:15AM CEST

Simcere Pharmaceutical Group Limited

No. 699-18, Xuanwu Road
Xuanwu District
Nanjing 210042
China
86 25 8556 6666
https://www.simcere.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 7.027

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Jinsheng Ren	Co-Founder, Chairman & CEO	953,4k	N/A	1962
Mr. Yushan Wan	CFO, Joint Company Secretary & Executive Director	898,58k	N/A	1970
Mr. Renhong Tang Ph.D.	Executive Director	1,17M	N/A	1981
Ms. Xi Wang	VP & Executive Director	227,37k	N/A	1983
Mr. Gaobo Zhou	Chief Investment Officer	N/A	N/A	1979
Mr. Quanfu Feng	Vice President of Marketing	N/A	N/A	1965
Dr. Tamas Oravecz Ph.D.	Senior VP & Chief Scientific Officer of Simcere Zaiming	N/A	N/A	N/A
Dr. Aik Han Goh	Senior VP & Chief Medical Officer	N/A	N/A	1975
Mr. Wang John	Senior Vice President	N/A	N/A	1961
Ms. Po Man Mak A.C.I.S., A.C.S., C.P.A., FCCA	Joint Company Secretary	N/A	N/A	1975

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. The company focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN, a simnotrelvir tablets/ritonavir tablets. The company also offers promotion services for pharmaceutical products. It has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize SIM0801 and other drugs in the Greater China region. In addition, the company engages in the manufacture of pharmaceutical ingredients; and property management business. Simcere Pharmaceutical Group Limited was founded in 1995 and is headquartered in Nanjing, China.

Corporate Governance

Simcere Pharmaceutical Group Limiteds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.